PE20142402A1 - Sintesis de compuestos de ester y acido borico - Google Patents

Sintesis de compuestos de ester y acido borico

Info

Publication number
PE20142402A1
PE20142402A1 PE2014001477A PE2014001477A PE20142402A1 PE 20142402 A1 PE20142402 A1 PE 20142402A1 PE 2014001477 A PE2014001477 A PE 2014001477A PE 2014001477 A PE2014001477 A PE 2014001477A PE 20142402 A1 PE20142402 A1 PE 20142402A1
Authority
PE
Peru
Prior art keywords
synthesis
ester
boric acid
acid compounds
halogen
Prior art date
Application number
PE2014001477A
Other languages
English (en)
Inventor
Vince Ammoscato
John E Bishop
Fang-Ting Chiu
Achim Geiser
Jean-Marc Gomez
Robert Hett
Christoph Koellner
Vithalanand R Kulkarni
Young Lo
Steven Munk
Iain Fraser Pickersgill
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142402(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20142402A1 publication Critical patent/PE20142402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

SE REFIERE A UN PROCESO PARA PREPARAR UN COMPUESTO DE ESTER BORICO DE FORMULA(I): DONDE R1 ES UN GRUPO ALIFATICO C1-C8, ARILO C6-C10, ENTRE OTROS; R2 ES HIDROGENO O HALOGENO; R3 ES HALOGENO Y CADA R4 Y R5, ES INDEPENDIENTEMENTE, ES UN GRUPO ALIFATICO C1-C12, AROMATICO C6-C14, ENTRE OTROS. DICHO PROCESO OFRECE UN MAYOR RENDIMIENTO.
PE2014001477A 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico PE20142402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55753504P 2004-03-30 2004-03-30

Publications (1)

Publication Number Publication Date
PE20142402A1 true PE20142402A1 (es) 2015-02-04

Family

ID=34968044

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2014001477A PE20142402A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico
PE2005000359A PE20060162A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico
PE2009001314A PE20110075A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester borico

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2005000359A PE20060162A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico
PE2009001314A PE20110075A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester borico

Country Status (41)

Country Link
US (14) US7714159B2 (es)
EP (5) EP2377868A1 (es)
JP (4) JP4558039B2 (es)
KR (1) KR100939598B1 (es)
CN (5) CN108329337B (es)
AR (3) AR049374A1 (es)
AT (1) ATE521612T1 (es)
AU (1) AU2005230930B2 (es)
BR (1) BRPI0509587A (es)
CA (4) CA2738706C (es)
CL (2) CL2010000350A1 (es)
CR (1) CR8653A (es)
CY (3) CY1112053T1 (es)
DK (4) DK2377869T3 (es)
DO (1) DOP2011000293A (es)
EA (1) EA012927B1 (es)
EC (1) ECSP066960A (es)
ES (3) ES2371652T3 (es)
FI (1) FI4008721T3 (es)
HK (4) HK1100004A1 (es)
HR (4) HRP20212002T1 (es)
HU (1) HUE056859T2 (es)
IL (3) IL178250A (es)
LT (2) LT3385267T (es)
ME (1) ME01975B (es)
MX (1) MX367324B (es)
MY (1) MY145427A (es)
NL (3) NL1028639C2 (es)
NO (4) NO338905B1 (es)
NZ (3) NZ598172A (es)
PE (3) PE20142402A1 (es)
PL (3) PL3385267T3 (es)
PT (4) PT3385267T (es)
RS (4) RS62738B1 (es)
SG (5) SG10201600029PA (es)
SI (3) SI2377869T1 (es)
TW (1) TWI386212B (es)
UA (1) UA90108C2 (es)
UY (3) UY28830A1 (es)
WO (1) WO2005097809A2 (es)
ZA (1) ZA200608689B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
DK2377869T3 (da) * 2004-03-30 2014-04-14 Millennium Pharm Inc Syntese af Bortezomib
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
UA97536C2 (en) 2007-08-06 2012-02-27 Милленниум Фармасьютикалз, Инк. Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
AU2008298694A1 (en) * 2007-09-12 2009-03-19 Dr. Reddy's Laboratories Ltd. Bortezomib and process for producing same
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
RS54020B1 (en) 2008-06-17 2015-10-30 Millennium Pharmaceuticals Inc. ORGANOBOR ESTAR UNITS AND THEIR PHARMACEUTICAL COMPOSITIONS
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2013204896A1 (en) * 2008-09-29 2013-05-16 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN101899062B (zh) * 2009-05-26 2015-04-15 上海威智医药科技有限公司 α-手性硼酸及硼酸酯的合成工艺
EP2443128B1 (en) 2009-06-19 2017-12-20 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
MX2012007341A (es) 2009-12-22 2012-07-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP2534159A1 (en) 2010-02-09 2012-12-19 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
CN101781326B (zh) * 2010-02-11 2013-08-21 福建南方制药股份有限公司 一种制备手性氨基硼酸的中间体及其制备方法
WO2011107912A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
US9061037B2 (en) * 2010-03-18 2015-06-23 Innopharma, Inc. Stable bortezomib formulations
KR20130036228A (ko) 2010-03-31 2013-04-11 밀레니엄 파머슈티컬스 인코퍼레이티드 1-아미노-2-사이클로프로필에틸보론산의 유도체
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US8884009B2 (en) 2010-10-14 2014-11-11 Synthon Bv Process for making bortezomib and intermediates for the process
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102206188B (zh) * 2011-04-08 2013-02-27 苏州二叶制药有限公司 N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法
US8497374B2 (en) 2011-05-12 2013-07-30 Scinopharm Taiwan, Ltd. Process for preparing and purifying bortezomib
CN102268029B (zh) * 2011-05-19 2013-10-09 苏州二叶制药有限公司 化合物（1s,2s,3r,5s）-蒎烷二醇-l-苯丙氨酸-l-亮氨酸硼酸酯的制备
MX2013015308A (es) 2011-06-22 2014-05-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
CN102351890B (zh) * 2011-09-30 2014-07-02 重庆泰濠制药有限公司 一种硼替佐米的合成方法
CN102492021B (zh) * 2011-12-13 2013-10-23 重庆泰濠制药有限公司 硼替佐米的制备工艺
BR112014015363A8 (pt) 2011-12-22 2017-06-13 Ares Trading Sa derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
CN103374026A (zh) * 2012-04-27 2013-10-30 重庆医药工业研究院有限责任公司 一种硼替佐米中间体的制备方法
CN103450331B (zh) * 2012-06-05 2016-05-25 山东新时代药业有限公司 一种硼替佐米的精制方法
JP2015532915A (ja) 2012-09-11 2015-11-16 シプラ・リミテッド ボルテゾミブの製造方法
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
NZ630287A (en) 2012-11-16 2016-07-29 Shilpa Medicare Ltd Crystalline bortezomib process
PT2928898T (pt) 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2986619A1 (en) 2013-04-16 2016-02-24 Cipla Limited Process for the preparation of bortezomib mannitol ester
CN104211758B (zh) * 2013-05-29 2020-06-12 深圳翰宇药业股份有限公司 一种硼替佐米的制备方法
CN103497233B (zh) * 2013-09-30 2015-04-08 哈药集团技术中心 一种硼替佐米的制备方法
CN103554219A (zh) * 2013-10-01 2014-02-05 昆明贵研药业有限公司 一种制备硼替佐米的方法
KR101691353B1 (ko) * 2013-12-09 2016-12-30 주식회사 경보제약 보르테조밉의 제조방법 및 그의 신규 중간체
CN106132970B (zh) 2014-02-03 2020-09-04 俄亥俄州创新基金会 硼酸酯和其药物制剂
UA121389C2 (uk) 2014-05-20 2020-05-25 Мілленніум Фармасьютікалз, Інк. Борвмісні інгібітори протеасом для застосування після первинної протиракової терапії
EP3882252A1 (en) 2014-06-11 2021-09-22 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6420629B2 (ja) * 2014-10-30 2018-11-07 ボーグワーナー インコーポレーテッド チェーンガイドおよびチェーンテンショナアーム
DE102015204151A1 (de) * 2015-03-09 2016-09-15 Adidas Ag Ball, insbesondere Fußball, und Verfahren zur Herstellung eines Balls
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
EP3583110A1 (en) 2017-02-17 2019-12-25 Fresenius Kabi Oncology Ltd An improved process for the preparation of boronic acid esters
CN117398398A (zh) 2017-03-06 2024-01-16 云顶新耀新加坡有限公司 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11414437B2 (en) 2017-07-28 2022-08-16 Chengdu Origin Biotechnology Limited Company Borate compound, and synthesis method therefor and uses thereof
US10927133B2 (en) * 2017-09-02 2021-02-23 Sun Pharmaceutical Industries Limited Process for the preparation of ixazomib citrate
CN111187336B (zh) * 2018-11-14 2022-05-20 正大天晴药业集团股份有限公司 硼替佐米的精制方法
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525309A (en) * 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4537773A (en) * 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4701545A (en) * 1986-02-12 1987-10-20 Washington State University Research Foundation, Inc. Preparation of α,α-dihaloalkyl boronic esters
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
DK1355910T3 (da) * 2001-01-25 2011-06-27 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulering af borsyreforbindelser
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
WO2003033507A1 (fr) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
DK2377869T3 (da) 2004-03-30 2014-04-14 Millennium Pharm Inc Syntese af Bortezomib
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EP2443128B1 (en) * 2009-06-19 2017-12-20 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters

Also Published As

Publication number Publication date
AR049374A1 (es) 2006-07-26
CA2738706A1 (en) 2005-10-20
SG10201800972PA (en) 2018-03-28
HK1246300A1 (zh) 2018-09-07
DK1756121T3 (da) 2012-01-09
ES2457593T3 (es) 2014-04-28
UA90108C2 (uk) 2010-04-12
EP2377868A1 (en) 2011-10-19
PE20060162A1 (es) 2006-04-07
US20210171574A1 (en) 2021-06-10
ATE521612T1 (de) 2011-09-15
US20160362449A1 (en) 2016-12-15
NZ550522A (en) 2010-08-27
EP4008721A1 (en) 2022-06-08
MY145427A (en) 2012-02-15
SG182999A1 (en) 2012-08-30
US20180044377A1 (en) 2018-02-15
CN107474062A (zh) 2017-12-15
IL219853A0 (en) 2012-06-28
CN111925385B (zh) 2023-11-21
NO20171939A1 (no) 2006-12-22
SG151322A1 (en) 2009-04-30
CR8653A (es) 2007-10-23
US8283467B2 (en) 2012-10-09
CA2853272A1 (en) 2005-10-20
CN103396427A (zh) 2013-11-20
PE20110075A1 (es) 2011-02-17
WO2005097809A3 (en) 2006-02-16
PL3385267T3 (pl) 2022-02-14
EA012927B1 (ru) 2010-02-26
CN1960996B (zh) 2016-04-20
JP2016056180A (ja) 2016-04-21
UY34969A (es) 2015-02-27
CN1960996A (zh) 2007-05-09
NZ586824A (en) 2012-03-30
JP2007530687A (ja) 2007-11-01
US20050240047A1 (en) 2005-10-27
HRP20240307T3 (hr) 2024-05-10
HRP20140339T1 (hr) 2014-05-09
CA2560886C (en) 2014-08-12
IL178250A0 (en) 2006-12-31
ZA200608689B (en) 2007-09-26
AR097310A2 (es) 2016-03-02
CA2560886A1 (en) 2005-10-20
NL1033190A1 (nl) 2007-04-23
US9862745B2 (en) 2018-01-09
CN103396427B (zh) 2018-04-13
AR097309A2 (es) 2016-03-02
EP4008721B1 (en) 2024-01-03
US10000529B2 (en) 2018-06-19
BRPI0509587A (pt) 2007-09-25
TW200616646A (en) 2006-06-01
JP5894952B2 (ja) 2016-03-30
CY1112053T1 (el) 2015-11-04
EP2377869A1 (en) 2011-10-19
EP3385267B1 (en) 2021-09-29
CN111925385A (zh) 2020-11-13
ME01975B (me) 2015-05-20
KR100939598B1 (ko) 2010-02-01
US7714159B2 (en) 2010-05-11
EP2377869B1 (en) 2014-01-29
PL2377869T3 (pl) 2014-07-31
HRP20110846T1 (hr) 2011-12-31
JP5414625B2 (ja) 2014-02-12
PT4008721T (pt) 2024-03-21
IL219853A (en) 2015-05-31
AU2005230930A1 (en) 2005-10-20
US20190112334A1 (en) 2019-04-18
EP1756121A2 (en) 2007-02-28
NO20191065A1 (no) 2006-12-22
SI1756121T1 (sl) 2012-03-30
JP2010241816A (ja) 2010-10-28
PL1756121T3 (pl) 2012-02-29
US20200157143A1 (en) 2020-05-21
LT3385267T (lt) 2021-11-10
EP3385267A1 (en) 2018-10-10
CN108329337A (zh) 2018-07-27
PT1756121E (pt) 2011-11-30
PT2377869E (pt) 2014-04-15
US20220204558A1 (en) 2022-06-30
RS65253B1 (sr) 2024-03-29
IL219856A (en) 2015-05-31
IL219856A0 (en) 2012-06-28
SG10201600029PA (en) 2016-02-26
UY28830A1 (es) 2005-09-30
ES2899606T3 (es) 2022-03-14
HUE056859T2 (hu) 2022-03-28
DK2377869T3 (da) 2014-04-14
SG182998A1 (en) 2012-08-30
NL1028639C2 (nl) 2007-01-17
RS51983B (en) 2012-02-29
US20130005968A1 (en) 2013-01-03
KR20070007873A (ko) 2007-01-16
NL1028639A1 (nl) 2005-10-20
HRP20212002T1 (hr) 2022-04-01
JP6193960B2 (ja) 2017-09-06
US20210395301A1 (en) 2021-12-23
NO343966B1 (no) 2019-07-29
NL1033189A1 (nl) 2007-10-22
EP1756121B1 (en) 2011-08-24
NZ598172A (en) 2013-08-30
SI2377869T1 (sl) 2014-05-30
CL2010000350A1 (es) 2011-01-28
CY1124753T1 (el) 2022-07-22
CL2014002252A1 (es) 2014-12-05
FI4008721T3 (fi) 2024-03-19
CA2738706C (en) 2014-10-14
UY35578A (es) 2016-01-08
US20180265546A1 (en) 2018-09-20
CA2859119A1 (en) 2005-10-20
ES2371652T3 (es) 2012-01-05
NO20064893L (no) 2006-12-22
WO2005097809A2 (en) 2005-10-20
NL1033189C2 (nl) 2008-08-14
US20150038706A1 (en) 2015-02-05
NO338905B1 (no) 2016-10-31
JP4558039B2 (ja) 2010-10-06
NO344610B1 (no) 2020-02-10
HK1257298A1 (zh) 2019-10-18
CY1115336T1 (el) 2017-01-04
US20190330270A1 (en) 2019-10-31
PT3385267T (pt) 2021-11-23
EA200601795A1 (ru) 2007-04-27
DOP2011000293A (es) 2011-12-15
US20100174072A1 (en) 2010-07-08
DK4008721T3 (da) 2024-03-25
HK1100004A1 (en) 2007-08-31
ECSP066960A (es) 2006-12-20
RS53259B (en) 2014-08-29
NO20161350A1 (no) 2006-12-22
MX367324B (es) 2019-08-15
HK1164320A1 (en) 2012-10-19
IL178250A (en) 2012-06-28
AU2005230930B2 (en) 2011-09-29
RS62738B1 (sr) 2022-01-31
US20200369722A1 (en) 2020-11-26
LT4008721T (lt) 2024-03-25
SI3385267T1 (sl) 2022-04-29
DK3385267T3 (da) 2021-11-01
JP2013100378A (ja) 2013-05-23
CN108329337B (zh) 2021-06-25
NL1033190C2 (nl) 2007-11-27
TWI386212B (zh) 2013-02-21

Similar Documents

Publication Publication Date Title
PE20142402A1 (es) Sintesis de compuestos de ester y acido borico
ES2531396T3 (es) Proceso para preparar compuestos de piridinona
EA200870321A1 (ru) Способ получения 4-оксохинолинового соединения
EA201170096A1 (ru) Замещенные производные пиримидона
ECSP099091A (es) Profarmaco de compuesto de cinamida
CU23337B7 (es) Resolución de sal quiral
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
EA201490445A1 (ru) Циклопропанаминовое соединение
RU2011133749A (ru) Способ получения и выделения 2-ациламино-3-дифенилпропионовой кислоты
AR051392A1 (es) Antagonistas no peptidicos de bradiquinina y composiciones farmaceuticas de los mismos
EA200500268A1 (ru) Производные диоксан-2-алкилкарбаматов, способ их получения и применение в терапии
BRPI0510399A (pt) processo de preparo de derivados n-piperidino-1,5-difenilpirazol-3-carboxamida
EA201200282A1 (ru) Региоселективное получение производных 2-амино-5-трифторметилпиримидина
RU2020108470A (ru) Аддитивная композиция для культуральной среды, аддитивное соединение для культуральной среды и способ культивирования клеток или тканей с использованием этой композиции и соединения
AR047810A1 (es) Proceso quimico
PE20061421A1 (es) Compuestos de n-formil-hidroxilamina como inhibidores de peptidil-desformilasa
CR11578A (es) Derivados de oxadiazol activos e 1-fosfato de esfingosina
DK1970372T3 (da) Salte af 9-oxoacridin-10-eddikesyre med 1-alkylamino-1-deoxy-polyoler
EA200501530A1 (ru) Новые соединения бензотиадиазина, способ их получения и фармацевтические композиции, которые их содержат
AR045089A1 (es) "proceso para la preparacion de inhibidores de la cpla2"
AR059613A1 (es) Proceso para la preparacion de compuestos de dibenzotiazepina
RU2011105303A (ru) Способ получения n-алкил (алкил) акриламидов
BR112013005823B8 (pt) Compostos heterocíclicos para o tratamento ou prevenção de distúrbios causados pela neurotransmissão reduzida de serotonina, norefnefrina ou dopamina
RU2007146932A (ru) Производное соли 3,4-дигидроизохинолиния
EA200600502A1 (ru) Способ асимметрической гидрогенизации бета-аминокетонов

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
AE Restoration of lapsed or forfeited application
FC Refusal